Literature DB >> 19064891

In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing.

Cornelia Lass-Flörl1, Ana Alastruey-Izquierdo, Manuel Cuenca-Estrella, Susanne Perkhofer, Juan Luis Rodriguez-Tudela.   

Abstract

This study presents in vitro susceptibility data for clinical (n = 48) and environmental (n = 31) isolates of Aspergillus terreus against nine antifungal agents. The methodology of the European Committee on Antimicrobial Susceptibility Testing was applied. Posaconazole and anidulafungin had the lowest and amphotericin B the highest MICs. No differences in susceptibility patterns were observed between environmental and clinical isolates.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19064891      PMCID： PMC2630662          DOI： 10.1128/AAC.00335-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.

Authors:  Kieren A Marr; Rachel A Carter; Fulvio Crippa; Anna Wald; Lawrence Corey
Journal:  Clin Infect Dis       Date:  2002-02-26       Impact factor: 9.079

Review 2.  Infections due to emerging and uncommon medically important fungal pathogens.

Authors:  T J Walsh; A Groll; J Hiemenz; R Fleming; E Roilides; E Anaissie
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

3.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 4.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 5.  Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

6.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Authors:  Thomas J Walsh; Peter Pappas; Drew J Winston; Hillard M Lazarus; Finn Petersen; John Raffalli; Saul Yanovich; Patrick Stiff; Richard Greenberg; Gerald Donowitz; Mindy Schuster; Annette Reboli; John Wingard; Carola Arndt; John Reinhardt; Susan Hadley; Robert Finberg; Michél Laverdière; John Perfect; Gary Garber; Giuseppe Fioritoni; Eli Anaissie; Jeanette Lee
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

7.  Mitochondrial cytochrome b gene analysis of Aspergillus fumigatus and related species.

Authors:  L Wang; K Yokoyama; M Miyaji; K Nishimura
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

Review 8.  Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature.

Authors:  P C Iwen; M E Rupp; A N Langnas; E C Reed; S H Hinrichs
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

9.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

10.  Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).

Authors:  Ana Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948
View more
  23 in total

1.  Aspergillus terreus infection in a sutureless self-sealing incision made during cataract surgery.

Authors:  Elif Erdem; Hazal Kandemir; Sevtap Arıkan-Akdağlı; Ebru Esen; Arbil Açıkalın; Meltem Yağmur; Macit İlkit
Journal:  Mycopathologia       Date:  2014-11-02       Impact factor: 2.574

2.  Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.

Authors:  M Pfaller; L Boyken; R Hollis; J Kroeger; S Messer; S Tendolkar; D Diekema
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

3.  Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

Authors:  A Espinel-Ingroff; D J Diekema; A Fothergill; E Johnson; T Pelaez; M A Pfaller; M G Rinaldi; E Canton; J Turnidge
Journal:  J Clin Microbiol       Date:  2010-06-30       Impact factor: 5.948

4.  Evaluation of Etest performed in Mueller-Hinton agar supplemented with glucose for antifungal susceptibility testing of clinical isolates of filamentous fungi.

Authors:  E Pinto; M Lago; L Branco; L A Vale-Silva; M D Pinheiro
Journal:  Mycopathologia       Date:  2014-02-26       Impact factor: 2.574

5.  In vitro activities of amphotericin B, terbinafine, and azole drugs against clinical and environmental isolates of Aspergillus terreus sensu stricto.

Authors:  Mariana S Fernández; Florencia D Rojas; María E Cattana; María de Los Ángeles Sosa; Cristina A Iovannitti; Cornelia Lass-Flörl; Gustavo E Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

6.  Species Identification and In Vitro Antifungal Susceptibility of Aspergillus terreus Species Complex Clinical Isolates from a French Multicenter Study.

Authors:  E Dannaoui; F Botterel; S Imbert; A C Normand; S Ranque; J M Costa; J Guitard; I Accoceberry; C Bonnal; A Fekkar; N Bourgeois; S Houzé; C Hennequin; R Piarroux
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

Authors:  A Espinel-Ingroff; A Fothergill; J Fuller; E Johnson; T Pelaez; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

8.  In vitro activity and in vivo efficacy of posaconazole in treatment of murine infections by different isolates of the Aspergillus terreus complex.

Authors:  Valentina Salas; F Javier Pastor; M M Rodríguez; Enrique Calvo; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

9.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

10.  Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.

Authors:  Alicia López-Sánchez; Alba Pérez-Cantero; Carlos Torrado-Salmerón; Adela Martin-Vicente; Víctor García-Herrero; María Ángeles González-Nicolás; Alberto Lázaro; Alberto Tejedor; Santiago Torrado-Santiago; Juan José García-Rodríguez; Javier Capilla; Susana Torrado
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.